Clinical trials: SARS-COV2
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion
This is the first-in-human phase 1/2a trial of the intravenous administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631666
- Testing
- DZIF-10c
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Cologne
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Phase 1 To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 Phase 2 To evaluate the…
- Trial name
- NCT04425629
- Testing
- casirivimab+imdevimab combination therapy
- Where
- 114 sites in United States, Mexico and 1 more
- Volunteers
- 10,078 people
- Sponsor
- Regeneron Pharmaceuticals
Depression, COVID-19
Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks…
- Trial name
- TELESPHOR (NCT05323994)
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Servier Russia
SARS-CoV-2 Infection
Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）
The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.
- Trial name
- NCT05065619
- Testing
- MT-2766 High dose (3.75 µg), MT-2766 Low dose
- Where
- 3 sites in Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID
Sarilumab for Patients With Moderate COVID-19 Disease
Objectives: To determine whether blockade of IL-6R is beneficial in patients with COVID-19 infection of moderate severity. Research Design: Randomized, controlled trial.
- Trial name
- NCT04359901
- Testing
- SARILUMAB
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Westyn Branch-Elliman
SARS-CoV-2 Infection
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
This was a Phase 2/3 study to assess the efficacy about therapeutic effect of CT-P59 to the mild to moderate SARS-CoV-2 infected patients and the safety during after study drug injection.
- Trial name
- NCT04602000
- Testing
- CT-P59
- Where
- South Korea
- Volunteers
- 1,642 people
- Sponsor
- Celltrion
Covid19, Anosmia
Smell in Covid-19 and Efficacy of Nasal Theophylline
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even…
- Conditions
- Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic
- Trial name
- SCENT2 (NCT04789499)
- Testing
- Theophylline Powder
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Influenza
A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
The purpose of this research is to determine if the use of a new device can accurately detect a virus infection.
- Trial name
- NCT05674370
- Testing
- GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic